

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2025 (09.01.2025)



(10) International Publication Number
WO 2025/008773 A1

(51) International Patent Classification:

C07F 9/6558 (2006.01) *A61P 35/00* (2006.01)
A61K 31/655 (2006.01) *C07F 9/655* (2006.01)
A61K 31/675 (2006.01) *C07F 9/6561* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/IB2024/056519

(22) International Filing Date:

03 July 2024 (03.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/524,820 03 July 2023 (03.07.2023) US

(71) Applicant: **LUNELLA BIOTECH, INC.** [CA/CA]; 145
Richmond Road, Ottawa, Ontario K1Z 1A1 (CA).

(72) Inventors: **LISANTI, Michael P.**; 842 Wilmslow Road,
Flat 27, Philip Godlee Lodge, Didsbury Village Greater
Manchester M20 2DS (GB). **SOTGIA, Federica**; 842
Wilmslow Road, Flat 27, Philip Godlee Lodge, Dids-
bury Village Greater Manchester M20 2DS (GB). **KAN-
GASMETSA, Jussi**; 119 Clay Farm Drive, Cambridge
Cambridgeshire CB2 9BX (GB). **DIPISA, Filippo**; 43
Greenwood Terrace, Salford Greater Manchester M5 3GH
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITOR COMPOUNDS

(57) Abstract: Mitochondria specific transcription inhibitors may be used to target and eliminate cancer stem cells and may be used as therapeutic agents for the treatment of cancer, including reducing the likelihood of and/or preventing tumor recurrence and metastasis. The mitochondria specific transcription inhibitor compounds disclosed herein have demonstrated inhibition of tumorsphere forming capacity, migration and stemness-related signaling in cancer stem cells. These properties result from selective inhibiting of mitochondrial transcription targeting mitochondrial RNA polymerase (POLRMT) in cancer cells.

WO 2025/008773 A1